Document is current
Any future updates will be listed below
-
Authors
Kou, Samuel
Kile, Sammi
Kambampati, Sai Samhith
Brady, Evelyn C.
Wallace, Hayley
De Sousa, Carlos M.
Cheung, Kin
Dickey, Lauren
Wentworth, Kelly L.
Hsiao, Edward C. http://orcid.org/0000-0001-8924-106X
-
Funding
Funding for this research was provided by:
Department of Medicine, University of California, San Francisco (The Robert L. Kroc Chair in Rheumatic, Connective Tissue Diseases III)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01-AR0703015)
- License Information
-
More Information
Article History
Received: 8 September 2021
Accepted: 13 February 2022
First Online: 4 March 2022
Declarations
:
: The study was approved by the Institutional Review Board at the University of California (approval number 20-30734). Subjects were consented to this protocol. Physicians also provided anonymous data separate from the consent of subjects. The FOP Registry was approved by the central institutional review board, Advarra (approval number CR00263401). Participants gave their consent to participate in the FOP Registry.
: Written consent for publication of the clinical images was obtained from the subject.
: ECH serves in a volunteer capacity on the Medical Registry Advisory Board of the International Fibrodysplasia Ossificans Progressiva Association. ECH serves in a volunteer capacity on the Fibrous Dysplasia Foundation Medical Advisory Board. ECH is a member of the International Clinical Council on FOP. ECH, EB, SSK, CDS, and LD receive clinical trials support from Clementia Pharmaceuticals, an Ipsen Company. ECH received prior funding from Regeneron Pharmaceuticals and Neurocrine Biosciences for clinical trial activities. S Kile and KC are supported by the International FOP Association. These pose no conflicts for this study.
